The global antidiabetics market is on a strong growth trajectory, with sales projected to soar from USD 106.3 billion in 2024 to USD 298.2 billion by 2034. This substantial increase reflects a robust ...

Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

The global orphan drug market size was USD 154.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.3 % ...

Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version ...

The drugs are listed in alphabetical order. Aprepitant oral suspension: Merck reported a shortage of Emend, its aprepitant oral suspension. Merck did not provide a reason for the shortage. The ...

Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...

The Europe Antibiotics Market is witnessing steady growth, driven by the increasing prevalence of infectious diseases, an aging population, and advancements in diagnostic capabilities. These factors ...

The severity of a patient’s chronic spontaneous urticaria impacted several outcomes, including quality of life and treatment ...

In this report the analyst provides an in-depth analysis of the key themes, strategic moves, and market dynamics presented at the conference, offering insights into how major players are positioning ...

Israeli drug manufacturer Teva Pharmaceutical Industries has resumed the deliveries of the scarce epilepsy drug Finlepsin ...